Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Operating Leases: 2019-2025

Historic Operating Leases for Tg Therapeutics (TGTX) over the last 7 years, with Sep 2025 value amounting to $7.3 million.

  • Tg Therapeutics' Operating Leases fell 13.20% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 13.20%. This contributed to the annual value of $8.1 million for FY2024, which is 11.89% down from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Operating Leases is $7.3 million, which was down 3.69% from $7.6 million recorded in Q2 2025.
  • Tg Therapeutics' Operating Leases' 5-year high stood at $10.6 million during Q3 2022, with a 5-year trough of $7.3 million in Q3 2025.
  • Its 3-year average for Operating Leases is $8.7 million, with a median of $8.7 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first climbed by 5.61% in 2022, then decreased by 13.20% in 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Leases (Quarterly) stood at $9.8 million in 2021, then grew by 5.05% to $10.3 million in 2022, then fell by 10.76% to $9.2 million in 2023, then fell by 11.89% to $8.1 million in 2024, then fell by 13.20% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $7.6 million for Q2 2025, and $7.9 million during Q1 2025.